Dengue Fever

Overview
Pathogen Biology
Transmission & Epidemiology
Symptoms by Phase
Diagnosis
Treatment
Home & Supportive Care
Complications
Prevention & Vaccines
Key Research Papers
Connections
Featured Videos

1. Overview

Dengue fever is the world's most prevalent mosquito-borne viral illness, infecting an estimated 390 million people each year and posing a risk to roughly half the global population. Caused by any of four antigenically distinct dengue virus serotypes (DENV-1 through DENV-4), dengue ranges from a self-limiting febrile illness to the potentially life-threatening dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS).

The disease is caused by flaviviruses transmitted primarily by Aedes aegypti mosquitoes and, to a lesser extent, Aedes albopictus. First clearly described in the 18th century, dengue has expanded dramatically over the past 50 years with urbanization, global travel, and mosquito range expansion. It is endemic in more than 100 countries across tropical and subtropical regions of the Americas, Southeast Asia, the Western Pacific, Africa, and the Eastern Mediterranean.

There is no specific antiviral therapy for dengue; management is supportive. Early recognition of warning signs — abdominal pain, persistent vomiting, rapid breathing, bleeding, fatigue, liver enlargement, and rising hematocrit with rapid fall in platelet count — is critical to preventing death, which occurs in fewer than 1% of detected cases when appropriate care is provided but can exceed 20% in severe dengue without treatment.

2. Pathogen Biology

Dengue virus (DENV) is a positive-sense single-stranded RNA virus belonging to the family Flaviviridae, genus Flavivirus. Its ~10.7 kb genome encodes three structural proteins — capsid (C), pre-membrane (prM), and envelope (E) — and seven nonstructural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, NS5).

Four Serotypes and Cross-Immunity

DENV-1, -2, -3, and -4 are genetically and antigenically distinct enough that infection with one serotype confers lifelong homotypic immunity but only transient (2–3 months) heterotypic protection. A second infection with a different serotype is associated with substantially higher risk of severe dengue, driven by antibody-dependent enhancement (ADE): pre-existing cross-reactive antibodies from the first infection bind the new serotype virus but fail to neutralize it; instead, they facilitate Fc receptor-mediated entry into monocytes and macrophages, amplifying viral replication 100-fold.

Envelope Protein and Cell Entry

The envelope (E) protein mediates receptor binding and fusion with host cell membranes following endocytosis. DENV infects dendritic cells, macrophages, monocytes, and endothelial cells. NS1 is secreted into the bloodstream and plays a central role in pathogenesis by disrupting endothelial tight junctions and activating complement, contributing to the capillary leak that defines severe dengue.

Cytokine Storm and Vascular Permeability

Severe dengue is characterized by a rapid cytokine storm involving TNF-alpha, IL-6, IL-8, CXCL10, and vascular endothelial growth factor (VEGF). This drives increased vascular permeability, plasma leakage into serous cavities (pleural effusion, ascites), and hemoconcentration. Thrombocytopenia results from virus-induced megakaryocyte suppression, platelet destruction by immune mechanisms, and consumption during coagulopathy.

3. Transmission & Epidemiology

Dengue is transmitted exclusively by mosquito bite — it is not contagious person-to-person (except rarely via blood transfusion, organ transplant, or vertical mother-to-infant transmission).

Vector Biology

Aedes aegypti is the primary vector: a day-biting, highly domesticated mosquito that breeds in small, clean, stagnant water containers (flower pots, discarded tires, water storage drums, buckets). It is abundant in tropical and subtropical urban environments. Aedes albopictus (tiger mosquito) is a secondary vector with a wider geographic range including temperate regions of Europe, North America, and East Asia.

The extrinsic incubation period in the mosquito is 8–12 days at temperatures above 25°C. A single infectious blood meal makes the mosquito capable of transmitting dengue for its entire lifespan. Temperature-sensitive vector competence means climate change is expanding dengue's geographic range.

Global Burden

WHO estimates 390 million dengue infections annually, of which approximately 96 million are clinically apparent. The Americas, Southeast Asia, and Western Pacific are the most heavily affected. Brazil, the Philippines, Vietnam, Indonesia, and Bangladesh together account for a large proportion of global cases. Dengue causes roughly 40,000 deaths per year, though this figure is likely an underestimate. Dengue is the leading cause of acute febrile illness in returning travelers from endemic regions.

Seasonality and Outbreaks

Dengue transmission correlates with rainy season when mosquito breeding sites proliferate. Major epidemic cycles occur every 3–5 years as dominant circulating serotypes shift. All four serotypes can co-circulate; introduction of a new serotype into a partially immune population is a predictor of severe disease outbreaks.

4. Symptoms by Phase

The WHO 2009 classification recognizes dengue without warning signs, dengue with warning signs, and severe dengue. Disease progresses through three overlapping clinical phases:

Febrile Phase (Days 1–3)

Abrupt onset of high fever (39–40°C), often called "breakbone fever" for its severe myalgia and arthralgia. Other features: frontal headache, retro-orbital pain (pain behind the eyes, worsened by eye movement), facial flushing, diffuse erythema, nausea, vomiting, and a positive tourniquet test (capillary fragility). The fever may be biphasic — defervescing then returning ("saddleback" pattern) — though this is less reliable diagnostically than formerly thought.

Critical Phase (Days 4–6)

Fever defervesces around days 3–7. This is the period of greatest danger. Plasma leakage peaks during the 24–48 hours around defervescence. In patients who will develop severe dengue, rapid platelet fall (often <100,000/mm³) and rising hematocrit (>20% above baseline) signal plasma leak. Warning signs that demand immediate hospital evaluation:

Abdominal pain or tenderness
Persistent vomiting (≥3 episodes in 1 hour)
Clinical fluid accumulation (ascites, pleural effusion)
Mucosal bleeding (gum bleeding, nosebleeds)
Lethargy or restlessness
Liver enlargement >2 cm
Laboratory: rising hematocrit with rapid platelet decline

Recovery Phase (Days 7–10)

Reabsorption of leaked plasma back into the intravascular space. Pulse slows, blood pressure improves, diuresis resumes. A second rash — described as "islands of white in a sea of red" — may appear. Bradycardia is common. Fluid overload becomes a concern if excessive IV fluids were given during the critical phase. Recovery is usually complete within 2–4 weeks; persistent fatigue and depression are reported in a minority of patients.

5. Diagnosis

Diagnosis integrates clinical suspicion (fever + relevant travel/residence history + classic symptoms) with laboratory confirmation. Dengue mimics many other febrile illnesses including malaria, chikungunya, Zika, leptospirosis, typhoid, and influenza.

NS1 Antigen Test

Dengue NS1 antigen is detectable in blood during the febrile phase (days 1–5). Rapid NS1 immunochromatographic tests have sensitivity of 70–95% and high specificity; false negatives increase after day 5. NS1 is the preferred test for early-phase dengue.

Dengue IgM/IgG Serology

IgM antibodies rise after day 4–5 and peak at 2 weeks; IgG rises later. In primary infection, IgM predominates. In secondary infection, IgG rises rapidly (anamnestic response). A single sample with IgM/IgG ratio or a paired sample showing fourfold IgG rise confirms the diagnosis. Serology is the method of choice after day 5 of illness.

RT-PCR

Reverse transcriptase-PCR detects dengue RNA during the febrile phase (days 1–5) with high sensitivity and specificity and can serotype the infecting strain. It is the gold standard for early confirmation and epidemiologic surveillance but requires laboratory infrastructure not universally available in endemic settings.

Full Blood Count

Leukopenia (WBC <5,000) is typical during dengue fever; it helps distinguish dengue from bacterial infection. Thrombocytopenia and rising hematocrit are the key laboratory warning signs. Serial CBC every 24 hours (or more frequently in patients with warning signs) guides fluid management decisions.

6. Treatment

There is no approved antiviral therapy for dengue. Treatment is supportive and stratified by severity.

Dengue Without Warning Signs (Home Management)

Rest and generous oral fluid intake (oral rehydration solution, fruit juice, water — 2–3 liters per day for adults).
Paracetamol (acetaminophen) for fever and pain — keep temperature below 39°C.
Avoid NSAIDs and aspirin — ibuprofen, naproxen, and aspirin inhibit platelet function and increase bleeding risk; aspirin specifically can cause Reye's syndrome in children.
Return immediately if warning signs appear.

Dengue with Warning Signs (Hospital Monitoring)

IV crystalloid fluid replacement (isotonic saline or Ringer's lactate) titrated to clinical response — start 5–7 mL/kg/hour and titrate based on hematocrit, urine output, and clinical signs.
Serial monitoring of hematocrit, platelet count, and vital signs.
Platelet transfusion is generally not indicated unless platelet count falls below 10,000/mm³ with active bleeding.
Careful fluid management to avoid both under-resuscitation (shock) and over-hydration (fluid overload during recovery).

Severe Dengue (ICU Care)

Dengue shock syndrome requires aggressive IV fluid resuscitation (10–20 mL/kg IV bolus of isotonic crystalloid), colloids for refractory shock. Severe hemorrhage may require fresh whole blood or packed red cells. Dengue with severe organ impairment (liver failure, encephalitis, myocarditis, acute kidney injury) is managed with organ-specific supportive care. Mortality with appropriate ICU care is below 1%.

7. Home & Supportive Care

For the majority of dengue patients managed at home, practical supportive measures significantly reduce discomfort and aid recovery:

Hydration: Drink frequently — set a timer to sip every 30 minutes. ORS, coconut water, and clear soups are excellent. Avoid caffeinated drinks and alcohol, which are dehydrating.
Fever management: Sponge with lukewarm (not cold) water. Paracetamol every 6 hours up to 4g/day for adults; avoid exceeding the dose to reduce liver strain (dengue can cause mild hepatitis).
Rest: Complete rest during the febrile phase reduces metabolic demand and aids immune response.
Monitoring at home: Check temperature twice daily, look for bleeding signs (gum bleeding, nosebleeds, blood in urine or stool, skin bruising), and track fluid intake and urine output.
Nutrition: Light, easy-to-digest foods — bananas, rice, toast, boiled vegetables. Nausea often reduces appetite; small frequent meals are better tolerated.
Mosquito protection during illness: Use mosquito nets and repellent while sick — a viremic patient can infect a mosquito that then infects others.

8. Complications

Dengue hemorrhagic fever (DHF): Defined by fever lasting 2–7 days, hemorrhagic manifestations, thrombocytopenia (platelet count ≤100,000/mm³), and evidence of plasma leakage. Most frequently occurs in secondary dengue infection or in infants with maternal antibodies.
Dengue shock syndrome (DSS): DHF with circulatory failure — rapid weak pulse, narrowing pulse pressure (≤20 mmHg) or hypotension. Fatal in up to 40% of cases if untreated; <1% with appropriate IV fluid management.
Expanded dengue syndrome: Unusual clinical manifestations including dengue encephalitis, myocarditis, hepatitis (ALT/AST 10x normal), nephritis, and acute respiratory distress. More common in elderly, obese, pregnant, or immunocompromised patients.
Congenital dengue: Maternal dengue near delivery can cause perinatal dengue in neonates with thrombocytopenia and hemorrhage.
Post-dengue fatigue syndrome: Weeks to months of persistent fatigue, cognitive difficulty, and depression following acute infection, particularly after severe disease.

9. Prevention & Vaccines

Vector Control

Eliminating Aedes breeding sites is the most effective community intervention: remove standing water from containers, cover water storage, use larvicides (Bacillus thuringiensis israelensis, temephos) in water that cannot be emptied, and deploy adult mosquito control via insecticide fogging during outbreaks. Sterile insect technique (SIT) and Wolbachia-infected mosquito releases are emerging biologic control strategies.

Personal Protection

DEET (30–50%) or picaridin-based repellents applied to exposed skin; permethrin-treated clothing; long sleeves and pants during peak biting hours (dawn and dusk, though Ae. aegypti also bites during the day); window screens and air conditioning.

Dengvaxia (CYD-TDV) Vaccine

The first licensed dengue vaccine (Sanofi Pasteur), a live attenuated chimeric tetravalent vaccine. Recommended only for individuals aged 9–45 years with documented prior dengue infection (seropositive). In seronegative individuals, the vaccine acts like a first dengue infection, paradoxically increasing severe dengue risk upon subsequent natural infection. Pre-vaccination screening for serostatus is mandatory in jurisdictions using Dengvaxia.

TAK-003 (Qdenga) Vaccine

Takeda's live attenuated tetravalent dengue vaccine approved in the European Union (2022), Indonesia, Brazil, and other countries for individuals aged 4–60 years. Demonstrated 61% overall efficacy against symptomatic dengue and 84% against hospitalized dengue in the TIDES phase 3 trial; did not require pre-vaccination seroscreening in trial populations, offering a key logistical advantage over Dengvaxia.

10. Key Research Papers

Bhatt S, Gething PW, Brady OJ, et al. The global distribution and burden of dengue. Nature. 2013;496:504–507. PMID: 23563266.
Halstead SB. Dengue antibody-dependent enhancement: knowns and unknowns. Microbiol Spectr. 2014. PMID: 26104722.
WHO. Dengue: Guidelines for Diagnosis, Treatment, Prevention and Control (2009 revision). Geneva: World Health Organization, 2009. PMID: 23762963.
Simmons CP, Farrar JJ, Nguyen VVC, Wills B. Dengue. N Engl J Med. 2012;366:1423–1432. PMID: 22494122.
Screaton G, Mongkolsapaya J, Yacoub S, Roberts C. New insights into the immunopathology and control of dengue virus infection. Nat Rev Immunol. 2015;15:745–759. PMID: 26603900.
Katzelnick LC, Gresh L, Halloran ME, et al. Antibody-dependent enhancement of severe dengue disease in humans. Science. 2017;358:929–932. PMID: 29097492.
Biswal S, Reynales H, Saez-Llorens X, et al. Efficacy of a tetravalent dengue vaccine in healthy children and adolescents. N Engl J Med. 2019;381:2009–2019. PMID: 31693806.
Capeding MR, Tran NH, Hadinegoro SRS, et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia. Lancet. 2014;384:1358–1365. PMID: 25018116.
Anders KL, Nguyet NM, Chau NV, et al. Epidemiological factors associated with dengue shock syndrome and mortality in hospitalized dengue patients in Ho Chi Minh City, Vietnam. Am J Trop Med Hyg. 2011;84:127–134. PMID: 21292889.
Duong V, Lambrechts L, Paul RE, et al. Asymptomatic humans transmit dengue virus to mosquitoes. Proc Natl Acad Sci USA. 2015;112:14688–14693. PMID: 26553981.
Hoffmann AA, Montgomery BL, Popovici J, et al. Successful establishment of Wolbachia in Aedes populations to suppress dengue transmission. Nature. 2011;476:454–457. PMID: 21866160.
Wilder-Smith A, Ooi EE, Horstick O, Wills B. Dengue. Lancet. 2019;393:350–363. PMID: 30696575.

Live PubMed Searches

Back to Table of Contents

Connections